Form 10-Q · Quarterly report
Zoetis 10-Q, filed Nov 5, 2026
- Filed
- CIK
- 0001555280
- Accession no.
- 0001555280-26-000050
Summary
Zoetis reported third-quarter 2026 revenue of $2.39 billion, down 1% from a year earlier, and net income attributable to Zoetis of $591 million, down 18%, while nine-month revenue was roughly flat at $7.12 billion and nine-month net income fell 8% to $1.88 billion. Zoetis said tariffs and other trade measures, disease outbreaks, foreign-exchange exposure and a 2026 accounting change for non-U.S. subsidiaries contribute to quarterly variability and could affect demand, costs and results.
Key points
- Third-quarter 2026 revenue was $2,391 million versus $2,422 million a year earlier, a 1% decline and a 2% decline on an operational basis.
- Third-quarter net income attributable to Zoetis was $591 million, down 18%; adjusted net income was $720 million, down 5% (down 7% operationally).
- Nine-month revenue was $7,121 million, essentially flat, while nine-month net income attributable to Zoetis was $1,883 million, down 8%.
- Zoetis began in 2026 reporting its subsidiaries outside the U.S. without the prior one-month financial reporting lag, an accounting-principle change it said causes quarterly variability.
- For the nine months ended September 30, 2026, about 45% of revenue was denominated in foreign currencies and about 55% in U.S. dollars, with currency changes adding roughly 1% to year-over-year revenue growth.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Overview of our business Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.